24-Nov-14 9:45 AM  CST

FDA Approved Painkiller Said to Have Deterrents Against Abuse

The FDA announced this week that the powerful painkiller Hysingla ER (hydrocodone bitartrate) might have qualities that may actually deter drug abuse. The FDA came under fire earlier this year for approving the pure hydrocodone painkillers, Hysingla ER and Zohydro ER; primarily due to a growing concern for the already epidemic issue is opioid drug abuse.

            Breaking, crushing and dissolving opioids such as Vicodin (hydrocodone/APAP) are ways abuser can receive an immediate high. Vicodin (hydrocodone/APAP), which was moved to a Class II status earlier this year, does not produce as much of a heightened effect as Hysingla ER or Zohydro ER because it is not purely hydrocodone. It is for this reason many in the medical field and pharmaceutical profession had growing concerns over the approval of Hysingla ER and Zohydro ER, but according to the latest findings by the FDA Hysingla ER will be substantially more difficult to break, crush or dissolve, making it a deterrent for those wishing to abuse it.

            The CDC states that approximately 15,000 people die each year from overdoses involving prescription painkillers. Hysingla ER and Zohydro ER are both intended to help those who suffer from chronic pain and need the help of prescription painkillers over long periods of time to ease their symptoms. In addition, Hysingla ER and Zohydro ER do not have the same liver damaging properties due to lack of acetaminophen within the drug’s make up.

            Medical professional across the United States still remain skeptical of Hysingla ER’s drug deterring properties. As one abuse specialist pointed out, abuse deterrences aren’t infallible. To make matters worse, since Hysingla ER and Zohydro ER are both pure hydrocodone, abusers would be able to reach a high very quickly, and this would only help fuel the abuse epidemic and increase the number of deaths related to prescription painkillers.

 

 

 

 

Resources:

Dennis, B. “FDA approves abuse-deterrent form of controversial painkiller”, 11-21-14, The Washington Post, http://www.washingtonpost.com/news/to-your-health/wp/2014/11/20/fda-approves-abuse-deterrent-form-of-controversial-painkiller/, referenced, 21.November 2014

Rabin, R. “FDA Hysingla, a Powerful Painkiller”, 11-20-14, The New York Times, http://www.nytimes.com/2014/11/21/science/fda-approves-hysingla-a-powerful-painkiller.html?_r=0, referenced, 21.November 2014

 


For additional information on this article, please contact:
 
 
Source: Sandy Andrews  

Tendenci™ User Home © 2004 Tendenci™ software by Schipul - "The Web Marketing Company" | www.schipul.com